Key result
The Mitroflow aortic pericardial bioprosthesis demonstrated effective orifice areas ranging from 1.4 to 1.8 cm2 and mean gradients from 10.6 to 15.1 mmHg across 19 to 25 mm valve sizes.
Population
55 patients, mean age 77.0 +/- 6.9 years, who received a Mitroflow aortic pericardial bioprosthesis.
Design
Cohort
Follow-up
mean 11.0 months
Authors
Loading...
May aid small-annulus patients by limiting mismatch; extends observational hemodynamics but leaves outcome impact open.
Observational (n=55)
The Mitroflow aortic pericardial bioprosthesis demonstrates acceptable in vivo effective orifice areas across all valve sizes, which may help avoid prosthesis-patient mismatch in patients with a small aortic annulus.
Jamieson et al. (2010) conducted an observational in Aortic valve replacement with Mitroflow bioprosthesis (n=55). Mitroflow aortic pericardial bioprosthesis was evaluated on Effective orifice area and transvalvular gradients. The Mitroflow aortic pericardial bioprosthesis demonstrated effective orifice areas ranging from 1.4 to 1.8 cm2 and mean gradients from 10.6 to 15.1 mmHg across 19 to 25 mm valve sizes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: